Temporal evolution of liver function parameters predicts clinical outcome in chronic heart failure patients (Bio-SHiFT study)
Abstract
Background: Liver dysfunction contributes to worse clinical outcomes in heart failure (HF) patients. However, studies exploring temporal evolutions of liver function parameters in chronic HF (CHF) pa- tients, and their associations with clinical outcome, are scarce. Detailed temporal patterns of alkaline phosphatase (ALP), gamma glutamyl transpeptidase (GGTP), total bilirubin (TBIL) and albumin (ALB) were investigated, and their relation with clinical outcome, in patients with stable CHF with reduced ejection fraction. Methods: Tri-monthly plasma samples were collected from 250 patients during 2.2 (1.4–2.5) years of follow-up. ALP, GGTP, ALB, and TBIL were measured in 749 selected samples and the relationship between repeatedly measured biomarker levels and the primary endpoint (PEP; composite of cardiovas- cular death, heart transplantation, left ventricular assist device implantation, and hospitalization for worsened HF) was evaluated by joint models. Results: Mean age was 66 ± 13 years; 74% were men, 25% in New York Heart Association class III–IV. 66 (26%) patients reached the PEP. Repeatedly measured levels of TBIL, ALP, GGTP, and ALB were associated with the PEP after adjustment for N-terminal prohormone B-type natriuretic peptide and high sensitivity troponin T (hazard ratio [95% confidence interval] per doubling of biomarker level: 1.98 [1.32; 2.95], p = 0.002; 1.84 [1.09; 3.05], p = 0.018, 1.33 [1.08; 1.63], p = 0.006 and 1.14 [1.09; 1.20], p < 0.001, respectively). Serial levels of ALP and GGTP, and slopes of the temporal evolutions of ALB and TBIL, adjusted for clinical variables, were also significantly associated with the PEP. Conclusions: Changes in serum levels of TBIL, ALP, GGTP, and ALB precede adverse cardiovascular events in patients with CHF. These routine liver function parameters may provide additional prognostic information in heart failure with reduced ejection fraction patients in clinical practice.
Keywords: heart failureliverbiomarkersheart failure with reduced ejection fractionrisk assessment
References
- Gerber Y, Weston SA, Redfield MM, et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med. 2015; 175(6): 996–1004.
- Biegus J, Hillege HL, Postmus D, et al. Abnormal liver function tests in acute heart failure: relationship with clinical characteristics and outcome in the PROTECT study. Eur J Heart Fail. 2016; 18(7): 830–839.
- Allen LA, Felker GM, Pocock S, et al. Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Eur J Heart Fail. 2009; 11(2): 170–177.
- van Deursen VM, Damman K, Hillege HL, et al. Abnormal liver function in relation to hemodynamic profile in heart failure patients. J Card Fail. 2010; 16(1): 84–90.
- Poelzl G, Ess M, Mussner-Seeber C, et al. Liver dysfunction in chronic heart failure: prevalence, characteristics and prognostic significance. Eur J Clin Invest. 2012; 42(2): 153–163.
- Goncalvesova E, Kovacova M. Heart failure affects liver morphology and function. What are the clinical implications? Bratisl Lek Listy. 2018; 119(2): 98–102.
- Kim M, Kato T, Farr M, et al. Hepatic dysfunction in ambulatory patients with heart failure. J Am Coll Cardiol. 2013; 61(22): 2253–2261.
- Correale M, Tarantino N, Petrucci R, et al. Liver disease and heart failure: Back and forth. Eur J Intern Med. 2018; 48: 25–34.
- Brankovic M, Akkerhuis KM, van Boven N, et al. Patient-specific evolution of renal function in chronic heart failure patients dynamically predicts clinical outcome in the Bio-SHiFT study. Kidney Int. 2018; 93(4): 952–960.
- Rizopoulos D. JM: An R package for the joint modelling of longitudinal and time-to-event data. J Statistical Software. 2010; 35(9).
- Suzuki K, Claggett B, Minamisawa M, et al. Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fraction. Eur J Heart Fail. 2020; 22(9): 1662–1671.
- Vishram-Nielsen JKK, Deis T, Balling L, et al. Relationship between invasive hemodynamics and liver function in advanced heart failure. Scand Cardiovasc J. 2019; 53(5): 235–246.
- Fuhrmann V, Kneidinger N, Herkner H, et al. Hypoxic hepatitis: underlying conditions and risk factors for mortality in critically ill patients. Intensive Care Med. 2009; 35(8): 1397–1405.
- Grodin JL, Lala A, Stevens SR, et al. Clinical Implications of Serum Albumin Levels in Acute Heart Failure: Insights From DOSE-AHF and ROSE-AHF. J Card Fail. 2016; 22(11): 884–890.
- Zeng M, Chen Yu, Zhao B. Higher liver stiffness in patients with chronic congestive heart failure: data from NHANES with liver ultrasound transient elastography. Ann Palliat Med. 2021; 10(6): 6859–6866.
- Taniguchi T, Ohtani T, Kioka H, et al. Liver stiffness reflecting right-sided filling pressure can predict adverse outcomes in patients with heart failure. JACC Cardiovasc Imaging. 2019; 12(6): 955–964.
- El Iskandarani M, El Kurdi B, Murtaza G, et al. Prognostic role of albumin level in heart failure: A systematic review and meta-analysis. Medicine (Baltimore). 2021; 100(10): e24785.
- Jabbour R, Ling HZ, Norrington K, et al. Serum albumin changes and multivariate dynamic risk modelling in chronic heart failure. Int J Cardiol. 2014; 176(2): 437–443.
- Peterson EJ, Ng TMH, Patel KA, et al. Association of admission vs. nadir serum albumin concentration with short-term treatment outcomes in patients with acute heart failure. J Int Med Res. 2018; 46(9): 3665–3674.
